search
Back to results

Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension

Primary Purpose

Hypertension

Status
Completed
Phase
Phase 4
Locations
Study Type
Interventional
Intervention
IRBESARTAN
Atenolol
Sponsored by
Sanofi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hypertension

Eligibility Criteria

18 Years - 80 Years (Adult, Older Adult)MaleDoes not accept healthy volunteers

Inclusion Criteria:

  • Hypertension grade 1 or 2
  • With at least two of the following criteria for the diagnosis of metabolic syndrome:

    • Body mass index > or = 25 kg/m2 AND waist circumference > or = 100 cm.
    • Dyslipidemia (triglycerides fasting serum levels > or = 200 mg/dL OR HDL serum levels < or = 40 mg/dL)
    • Fasting serum glucose > or = 110 mg/dL but < 126 mg/dL

Exclusion Criteria:

  • Known hypersensitivity to Irbesartan
  • Hypertension grade 3
  • History of clinical vascular events such as TIAs, stroke, peripheral arterial disease
  • Coronary artery disease
  • Renal insufficiency (creatinine serum levels > or = 1.2 mg/dL)
  • Presence of clinical heart failure
  • Asthma and COPD
  • Valvular cardiopathy clinically relevant
  • Current therapy with antioxidant drugs, statins
  • Therapy with AIIRA for at least 3 months during the last semester
  • Presence of any acute illness or major trauma in the last 8 weeks
  • History of a chronic inflammatory disease such as rheumatoid arthritis, immune disorders or connective tissue disease.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    Irbesartan Group

    Atenolol Group

    Arm Description

    150 mg p.o. once a day, 30 minutes before breakfast during 12 weeks

    50 mg p.o. once a day, 30 minutes before breakfast during 12 weeks.

    Outcomes

    Primary Outcome Measures

    Endothelial function in vivo qualification: brachial artery flow mediated vasodilation (FMV%) determined by high resolution ultrasound.

    Secondary Outcome Measures

    Full Information

    First Posted
    September 12, 2007
    Last Updated
    January 11, 2011
    Sponsor
    Sanofi
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00529750
    Brief Title
    Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension
    Official Title
    Comparative Trial of the Effects of Irbesartan vs Atenolol on the Endothelial Function of Hypertensive Patients With Metabolic Syndrome
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    January 2011
    Overall Recruitment Status
    Completed
    Study Start Date
    July 2002 (undefined)
    Primary Completion Date
    January 2005 (Actual)
    Study Completion Date
    January 2005 (Actual)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Sanofi

    4. Oversight

    5. Study Description

    Brief Summary
    Primary: To evaluate the impact of irbesartan on endothelial function in hypertensive patients with metabolic syndrome. Secondary: To evaluate the oxidative stress status in patients with hypertension with metabolic syndrome. To correlate the oxidative stress status with endothelial function in these patients. To evaluate the effect of irbesartan on the oxidative stress stage in patients with metabolic syndrome and to correlate it with the effect on endothelial function . To correlate the change in endothelial function and oxidative stress stage with the change of arterial pressure levels.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Hypertension

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Phase 4
    Interventional Study Model
    Parallel Assignment
    Masking
    ParticipantInvestigator
    Allocation
    Randomized
    Enrollment
    108 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Irbesartan Group
    Arm Type
    Experimental
    Arm Description
    150 mg p.o. once a day, 30 minutes before breakfast during 12 weeks
    Arm Title
    Atenolol Group
    Arm Type
    Active Comparator
    Arm Description
    50 mg p.o. once a day, 30 minutes before breakfast during 12 weeks.
    Intervention Type
    Drug
    Intervention Name(s)
    IRBESARTAN
    Intervention Description
    Tablets
    Intervention Type
    Drug
    Intervention Name(s)
    Atenolol
    Intervention Description
    Tablets
    Primary Outcome Measure Information:
    Title
    Endothelial function in vivo qualification: brachial artery flow mediated vasodilation (FMV%) determined by high resolution ultrasound.
    Time Frame
    at baseline and at the end of the study-12th wk

    10. Eligibility

    Sex
    Male
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    80 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Hypertension grade 1 or 2 With at least two of the following criteria for the diagnosis of metabolic syndrome: Body mass index > or = 25 kg/m2 AND waist circumference > or = 100 cm. Dyslipidemia (triglycerides fasting serum levels > or = 200 mg/dL OR HDL serum levels < or = 40 mg/dL) Fasting serum glucose > or = 110 mg/dL but < 126 mg/dL Exclusion Criteria: Known hypersensitivity to Irbesartan Hypertension grade 3 History of clinical vascular events such as TIAs, stroke, peripheral arterial disease Coronary artery disease Renal insufficiency (creatinine serum levels > or = 1.2 mg/dL) Presence of clinical heart failure Asthma and COPD Valvular cardiopathy clinically relevant Current therapy with antioxidant drugs, statins Therapy with AIIRA for at least 3 months during the last semester Presence of any acute illness or major trauma in the last 8 weeks History of a chronic inflammatory disease such as rheumatoid arthritis, immune disorders or connective tissue disease. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Juan Carlos Gomez
    Organizational Affiliation
    Sanofi
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Learn more about this trial

    Effect of the Angiotensin II Receptor Antagonist Irbesartan on Biochemical and Functional Markers of Endothelial Dysfunction in Patients With Hypertension

    We'll reach out to this number within 24 hrs